InflaRx N.V.
IFRXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Cantor Fitzgerald | maintain | Overweight | Aug 7, 2026 |
| Raymond James | upgrade | Outperform →Strong Buy | May 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 11, 2026 |
| Cantor Fitzgerald | maintain | Overweight | May 11, 2026 |
| Guggenheim | maintain | Buy | Apr 21, 2026 |
| Guggenheim | maintain | Buy | Mar 20, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 30, 2025 |
| Leerink Partners | downgrade | Outperform →Market Perform | Dec 3, 2025 |
| Guggenheim | maintain | Buy | Nov 10, 2025 |
| Oppenheimer | maintain | Outperform | May 29, 2025 |
| Guggenheim | maintain | Buy | Mar 26, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 25, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 24, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jan 25, 2024 |
| Raymond James | maintain | Strong Buy | Nov 2, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 12, 2023 |
Earnings History
Next report: Mar 18, 2027 · EPS est. $-0.05| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 3, 2026 | $-0.02 | $-0.06 | — | $6.1K |
| Aug 6, 2026 | $-0.11 | $-0.07 | — | $6.0K |
| May 7, 2026 | $-0.09 | $-0.17 | — | $9.0K |
| Mar 19, 2026 | $-0.17 | $-0.18 | -$17.6K | $27.3K |
| Nov 10, 2025 | $-0.16 | $-0.16 | $27.9K | $26.2K |
| Aug 7, 2025 | $-0.24 | $-0.24 | $46.4K | $26.0K |
| May 7, 2025 | $-0.14 | $-0.18 | — | $19.4K |
| Mar 20, 2025 | $-0.09 | $-0.27 | -$438.01 | $47.0K |
News
Travere Therapeutics (NASDAQ: TVTX - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. Profitability This table compares Travere Therapeutics and InflaRx's net
Jena, Germany, Nov. 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the peer-reviewed publication of first-in-human Phase 1 clinical data for izicopan, formerly known as INF904, the Company's orally administered, next-generation small molecule inhibitor of the C5a receptor (C5aR1). The publication reports results from the Company's single ascending dose (SAD) and mu…
InflaRx N.V. ( IFRX ) Analyst/Investor Day November 3, 2026 8:00 AM EST Company Participants Jan Medina - Head of Investor Relations & VP Niels Riedemann - Co-Founder, CEO & Executive Director Thomas Taapken - Chief Financial Officer Conference Call Participants Jörg Köhl Peter Merkel Yatin Suneja - Guggenheim Securities, LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Mazahir Alimohamed - Oppenheimer &…
InflaRx NASDAQ: IFRX outlined plans to advance its oral C5a receptor antagonist izicopan in ANCA-associated vasculitis (AAV), with an initial focus on patients with kidney involvement and a parallel study intended to evaluate corticosteroid reduction.
With a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in 2027, with first data readout anticipated in 2028 Phase 2 AAV izicopan program expected to include a placebo-controlled randomized study in patients with renal involvement with site initiation in early 2027, as well as an open-label “all-comers” study to demonstrate the ability to replace corticosteroids…
Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November.
Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology's Kidney Week 2026, taking place in Denver, Colorado, October 21 - 25. The in vivo and in vitro data demonstrated that izicopan robustly inhibited C5aR-mediated inflammatory responses …
Shares of InflaRx N.V. (NASDAQ: IFRX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has
Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology's Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 - 25.
Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026.
Event to be hosted on November 3, 2026 at 8:00 AM EST Featured speakers will include Peter A. Merkel, MD, MPH and Prof.
Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows: